$FENC has a nice short signal, the stock had a spectacular rally since it bottomed in early 2022, but could be reaching the end of the road here after drastically outperforming the market until now. Their drug received FDA approval in Sep 2022, commercial availability in the US in Oct 2022, but despite this, the latest report showed an increase in net loss YoY (twice as much as reported on Q3 2021). Seems like a decent short here, after this impressive run. Stop @ 9.95, support @ 8.
Best of luck!
Cheers,
Ivan Labrie.
Best of luck!
Cheers,
Ivan Labrie.
评论:
Off to a good start.
交易结束：到达止损:
相关观点
$F: Bullish trend
IvanLabrie
Premium
about F